Abstract
Objectives
Study design
Results
Conclusions
Implications
Keywords
1. Introduction
Government of Canada. Drug product database. Health Canada. 2017. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html [accessed 2017 Oct 1].
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition; 2015. Available: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1 [accessed 2017 June 29].
Royal College of Obstetricians and Gynaecologists. Best practice in comprehensive abortion care, Guideline Paper #2. Royal College of Obstetricians and Gynaecologists, 2015 June. Available at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/bpp2/ [accessed 2017 Oct 20].
World Health Organization. Clinical practice handbook for safe abortion. World Health Organization, 2014. ISBN: ISBN 978 92 4 154871 7. Available at: http://apps.who.int/iris/bitstream/10665/97415/1/9789241548717_eng.pdf [accessed 2017 Oct 20].
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition; 2015. Available: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1 [accessed 2017 June 29].
2. Materials and methods
3. Results

IUD | OCP | DMPA | Condom | Other | p | |
---|---|---|---|---|---|---|
n = 1247 | n = 1804 | n = 612 | n = 239 | n = 1304 | ||
Maternal age | 27.8±6.5 | 23.6±5.6 | 25.1±6.9 | 30.7±7.7 | 25.6±6.3 | <.001 |
Gravidity | 3.0±1.6 | 1.9±1.3 | 2.5±1.7 | 2.8±1.7 | 2.3±1.5 | <.001 |
Parity | 1.15±1.14 | 0.43±0.81 | 0.77±1.06 | 1.00±1.09 | 0.70±1.00 | <.001 |
Ever prior abortion | 556 (44.59) | 436 (24.17) | 211 (34.48) | 80 (33.47) | 450 (34.51) | <.001 |
Nulliparous | 448 (35.93) | 1321 (73.23) | 339 (55.39) | 109 (45.61) | 776 (59.46) | <.001 |

Parity adjusted odds ratio | 20–29-Year age group adjusted odds ratio | 30+-Year age group adjusted odds ratio | |
---|---|---|---|
2006 | 5.22 (3.13–8.98) *** | 2.60 (1.12–7.07) * | 3.49 (1.42–9.94) * |
2007 | 6.92 (4.29–11.46) *** | 2.11 (0.96–5.32) | 2.02 (0.85–5.36) |
2008 | 4.27 (2.74–6.75) *** | 1.70 (0.91–3.40) • | 1.52 (0.73–3.32) |
2009 | 2.35 (1.67–3.31) *** | 1.90 (1.24–2.97) ** | 1.53 (0.89–2.66) |
2010 | 1.76 (1.25–2.49) ** | 1.42 (0.93–2.17) | 1.48 (0.88–2.53) |
Total | 2.77 (2.40–3.20) *** | 1.87 (1.51–2.32) *** | 1.96 (1.54–2.50) *** |
1-Year odds ratio | 5-Year odds ratio | |
---|---|---|
IUD | Reference group | Reference group |
OCP | 1.98 (1.29–3.14)** | 1.96 (1.54–2.52) *** |
DMPA | 1.15 (0.61–2.09) | 1.84 (1.36–2.49)*** |
Other | 2.55 (1.65–4.03)*** | 2.14 (1.66–2.76)*** |
4. Discussion
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition; 2015. Available: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1 [accessed 2017 June 29].
The Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Intrauterine contraception. Current clinical guidance; 2015. Available from: http://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/ [accessed 2017 Aug 3].
BC Women's Hospital and Health Centre. Abortion & contraception resources: contraception — SMART program. Provincial Health Services Authority. Available from: http://www.bcwomens.ca/health-professionals/professional-resources/abortion-contraception-resources [accessed 2017 Aug 3].
Fédération du Québec pour le planning des naissances. Contraception in Quebec [Internet]. Montreal, Canada: Quebec Federation of Planned Parenthood; 2016. Available from: http://www.fqpn.qc.ca/public/informez-vous/contraception/la-contraception-au-quebec/ [accessed 2017 Nov 1].
Funding
Declaration of competing interests
References
- Canadian contraception consensus guidelines no. 329, (part 3 of 4: chapter 7).J Obstet Gynaecol Can. 2016 Feb; 38: 182-222
- Regulatory approval time for hormonal contraception in Canada, the United States and the United Kingdom, 2000–2015: a retrospective data analysis.CMAJ Open. 2016; 4: e654-e660
Government of Canada. Drug product database. Health Canada. 2017. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html [accessed 2017 Oct 1].
- Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion.Contraception. 2008; 78: 149-154
- Preventing repeat abortion in Canada: is the immediate insertion of intrauterine devices postabortion a cost-effective option associated with fewer repeat abortions?.Contraception. 2012; 85: 51-55
- Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion.Contraception. 2008; 78: 143-148
- Likelihood of repeat abortion in a Swedish cohort according to the choice of postabortion contraception: a longitudinal study.Acta Obstet Gynecol Scand. 2016; 95: 565-571
- Provision of intrauterine contraception in association with first trimester induced abortion reduces the need of repeat abortion: first-year results of a randomized controlled trial.Hum Reprod. 2015; 30: 2539-2546
- Impact of long-acting reversible contraception on return for repeat abortion.Am J Obstet Gynecol. 2012; 206: 37 e1-6
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition; 2015. Available: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1 [accessed 2017 June 29].
- Immediate postabortal insertion of intrauterine devices.Cochrane Database Syst Rev. 2014 Jul 28; 7CD001777
Royal College of Obstetricians and Gynaecologists. Best practice in comprehensive abortion care, Guideline Paper #2. Royal College of Obstetricians and Gynaecologists, 2015 June. Available at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/bpp2/ [accessed 2017 Oct 20].
- Increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy. Committee opinion no. 642.Obstet Gynecol. 2015 October; 126: 44-48
World Health Organization. Clinical practice handbook for safe abortion. World Health Organization, 2014. ISBN: ISBN 978 92 4 154871 7. Available at: http://apps.who.int/iris/bitstream/10665/97415/1/9789241548717_eng.pdf [accessed 2017 Oct 20].
- What proportion of Canadian women will accept an intrauterine contraceptive at the time of second trimester abortion? Baseline data from a randomized controlled trial.J Obstet Gynaecol Can. 2014; 36: 51-59
- Comparison of contraceptive method chosen by women with and without a recent history of induced abortion.Contraception. 2011; 84: 571-577
- Immediate postabortion intrauterine device insertion: continuation and satisfaction.Womens Health Issues. 2012; 22: e365-e369
- Contraceptive use among Canadian women of reproductive age: results of a national survey.J Obstet Gynaecol Can. 2009; 31: 626-640
- Effect of previous induced abortions on postabortion contraception selection.Contraception. 2015; 91: 398-402
- Trends and determinants of IUD use in the USA, 2002–2012.Hum Reprod. 2016; 31: 1696-1702
- Postabortion initiation of long-acting reversible contraception by adolescent and nulliparous women in New Zealand.J Adolesc Health. 2016; 58: 160-166
- Acceptance and continuation of contraceptive methods immediate postabortion.Gynecol Obstet Invest. 2017; 82: 86-95
American Academy of Pediatrics Contraception for adolescents. Pediatrics 2014;134(4):e1244–56.
- Adolescents and long-acting reversible contraception: implants and intrauterine devices. Committee opinion no. 539.Obstet Gynecol. 2012; 120: 983-988
The Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Contraceptive choices for young people. Current clinical guidance; 2010. Available from: http://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-young-people-mar-2010/ [accessed 2017 Aug 10].
- Use of intrauterine devices in nulliparous women.Contraception. 2017; 95: 529-537
- Long-acting reversible contraception: implants and intrauterine devices. Practice bulletin no. 121.Obstet Gynecol. 2011; 118: 184-196
The Faculty of Sexual and Reproductive Healthcare. UK medical eligibility criteria for contraceptive use; 2016. Available from: http://www.fsrh.org/standards-and-guidance/documents/ukmec-2016/ [accessed 2017 Aug 10].
The Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Intrauterine contraception. Current clinical guidance; 2015. Available from: http://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/ [accessed 2017 Aug 3].
- increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy.Obstet Gynecol. Dec 2009; 114: 1434-1438
- Board of the Society of Family Planning. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women.Contraception. 2010; 81: 367-371
BC Women's Hospital and Health Centre. Abortion & contraception resources: contraception — SMART program. Provincial Health Services Authority. Available from: http://www.bcwomens.ca/health-professionals/professional-resources/abortion-contraception-resources [accessed 2017 Aug 3].
Fédération du Québec pour le planning des naissances. Contraception in Quebec [Internet]. Montreal, Canada: Quebec Federation of Planned Parenthood; 2016. Available from: http://www.fqpn.qc.ca/public/informez-vous/contraception/la-contraception-au-quebec/ [accessed 2017 Nov 1].
- OHIP+: children and youth pharmacare [Internet].(Available from:) ([accessed 2017 Nov 1])Ontario Ministry of Health and Long-Term CareToronto, CanadaDate: 2017
Article info
Publication history
Footnotes
☆Funding: Support for this work was provided by the Michael Smith Foundation for Health Research, the Canadian Institutes of Health Research and the Public Health Agency of Canada (grant number CPP-137903).